Published in Gene Therapy Weekly, August 1st, 2002
Under the terms of the agreement, Orchid obtains rights to market cytochrome P450 2D6 (CYP2D6) testing services in North America. Orchid intends to offer CYP2D6 testing as part of the initial pharmacogenomics panel soon to enter beta testing under the aegis of its Orchid GeneShield unit, as well as in value-added genotyping products and services provided by its Orchid Life Sciences unit.
Financial details of the agreement were not disclosed.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.